{
    "id": 6124,
    "fullName": "NTRK2 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "NTRK2 positive indicates the presence of the NTRK2 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 4915,
        "geneSymbol": "NTRK2",
        "terms": [
            "NTRK2",
            "EIEE58",
            "GP145-TrkB",
            "OBHD",
            "trk-B",
            "TRKB"
        ]
    },
    "variant": "positive",
    "createDate": "05/15/2015",
    "updateDate": "08/23/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 3951,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD7451 treatment inhibited proliferation of a lung large-cell neuroendocrine carcinoma cell line expressing Ntrk2 in culture (PMID: 25054037).",
            "molecularProfile": {
                "id": 5968,
                "profileName": "NTRK2 positive"
            },
            "therapy": {
                "id": 2680,
                "therapyName": "AZD7451",
                "synonyms": null
            },
            "indication": {
                "id": 6658,
                "name": "pulmonary large cell neuroendocrine carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 792,
                    "pubMedId": 25054037,
                    "title": "Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451 in vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25054037"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3960,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GNF-4256 treatment inhibited BDNF-induced phosphorylation of Ntrk2 and growth of neuroblastoma cell lines expressing Ntrk2 in culture, and slowed tumor growth in the neuroblastoma cell line xenograft models (PMID: 25394774).",
            "molecularProfile": {
                "id": 5968,
                "profileName": "NTRK2 positive"
            },
            "therapy": {
                "id": 2653,
                "therapyName": "GNF-4256",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2684,
                    "pubMedId": 25394774,
                    "title": "TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25394774"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3963,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GNF-4256 worked synergistically with Camptosar (irinotecan) and Temodar (temozolomide), resulting in growth inhibition and an increased event-free survival in cell line xenograft models of neuroblastoma expressing Ntrk2 (PMID: 25394774).",
            "molecularProfile": {
                "id": 5968,
                "profileName": "NTRK2 positive"
            },
            "therapy": {
                "id": 3407,
                "therapyName": "GNF-4256 + Irinotecan + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2684,
                    "pubMedId": 25394774,
                    "title": "TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25394774"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16342,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ONO-7579 decreased NTRK2 phosphorylation and reduced migration, invasion, and proliferation of a gallbladder cell line expressing NTRK2 with wild-type KRAS in culture (PMID: 29599313).",
            "molecularProfile": {
                "id": 31607,
                "profileName": "KRAS wild-type NTRK2 pos"
            },
            "therapy": {
                "id": 8005,
                "therapyName": "ONO-7579",
                "synonyms": null
            },
            "indication": {
                "id": 3121,
                "name": "gallbladder cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14462,
                    "pubMedId": 29599313,
                    "title": "The Novel Selective Pan-TRK Inhibitor ONO-7579 Exhibits Antitumor Efficacy Against Human Gallbladder Cancer In Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29599313"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 5968,
            "profileName": "NTRK2 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31607,
            "profileName": "KRAS wild-type NTRK2 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}